IndustryCompany release

Anika Q3 revenue rises 10% as FDA deems Hyalofast PMA not approvable

🇺🇸 Anika Therapeutics, Inc. (ANIK) · Fri 06 Nov 2026

Anika Therapeutics reported third-quarter revenue of $30.6 million and raised parts of its 2026 guidance, but the FDA told it in October that its Hyalofast cartilage-repair application cannot be approved.

Anika Therapeutics reported third-quarter 2026 revenue of $30.6 million, up 10% on the same period a year earlier. Its Commercial Channel grew 17%. The company recorded a GAAP loss from continuing operations of $0.3 million.

On the strength of the quarter, Anika raised the low end of its 2026 revenue guidance and lifted its adjusted EBITDA guidance. The summary of the results does not give the revised figures.

The main regulatory setback came in October, when the US Food and Drug Administration notified Anika that its premarket approval (PMA) application for Hyalofast, a product for cartilage repair, is not approvable. The company said the decision rested mainly on the clinical data. The available information does not describe the agency's specific concerns or Anika's next steps for the product.

In November, Anika signed a new 10-year distribution agreement for Hyvisc with Boehringer Ingelheim. The company also said it expects to submit a new drug application (NDA) for Cingal before the end of 2027.

What it means for your team

  • A 'not approvable' notice on a PMA signals that the FDA considers the application deficient as submitted, here mainly on clinical evidence; teams planning device PMAs should note how heavily clinical data weigh in such decisions.
  • Anika's Cingal NDA is not expected until before year-end 2027, so a US decision on that product is some way off.
  • The new 10-year Hyvisc agreement with Boehringer Ingelheim sets a long-term distribution arrangement for that product, relevant to market-access and supply-chain planning for partners.

Company's press release (SEC filing): Anika Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Anika Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →